ZURNAI (AUTOINJECTOR) (nalmefene hydrochloride) by Purdue Pharma is clinical pharmacology pharmacodynamics nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Approved for opioid overdose. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ZURNAI is a nalmefene hydrochloride auto-injector that rapidly reverses opioid overdose by blocking opioid receptors in the brain. It prevents or reverses respiratory depression, sedation, and hypotension with a longer duration of action than naloxone. The drug is administered intramuscularly or subcutaneously and reaches therapeutic concentrations within 5–15 minutes.
Recently approved product in growth phase with strong IP protection through 2039; early-stage commercial infrastructure build-out will drive hiring across field and commercial operations.
CLINICAL PHARMACOLOGY Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone…
Worked on ZURNAI (AUTOINJECTOR) at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moZURNAI offers career entry into a high-impact emergency care space with Purdue Pharma's resources and infrastructure; the product's recent approval and growth-stage status present opportunities to build markets in underserved opioid overdose management. Long patent protection (13.5 years) ensures career stability and product investment.